🚀 VC round data is live in beta, check it out!
SanBio Valuation Multiples
Discover revenue and EBITDA valuation multiples for SanBio and similar public comparables like SPIMACO - ADDWAEIH, MedinCell, Keqian Biology, Gen İlaç and more.
SanBio Overview
About SanBio
SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.
Founded
2013
HQ
Employees
43
Website
Sectors
Financials (LTM)
EV
$941M
SanBio Financials
SanBio reported last 12-month revenue of $3M and negative EBITDA of ($25M).
In the same LTM period, SanBio generated ($25M) in EBITDA losses and had net loss of ($24M).
Revenue (LTM)
SanBio P&L
In the most recent fiscal year, SanBio reported revenue of — and EBITDA of ($19M).
SanBio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3M | XXX | — | XXX | XXX | XXX |
| EBITDA | ($25M) | XXX | ($19M) | XXX | XXX | XXX |
| EBITDA Margin | (888%) | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (892%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($24M) | XXX | ($18M) | XXX | XXX | XXX |
| Net Margin | (882%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
SanBio Stock Performance
SanBio has current market cap of $1B, and enterprise value of $941M.
Market Cap Evolution
SanBio's stock price is $13.18.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $941M | $1B | 0.3% | XXX | XXX | XXX | $-0.23 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSanBio Valuation Multiples
SanBio trades at 339.2x EV/Revenue multiple, and (38.2x) EV/EBITDA.
EV / Revenue (LTM)
SanBio Financial Valuation Multiples
As of April 19, 2026, SanBio has market cap of $1B and EV of $941M.
Equity research analysts estimate SanBio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
SanBio has a P/E ratio of (42.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $941M | XXX | $941M | XXX | XXX | XXX |
| EV/Revenue | 339.2x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | (38.2x) | XXX | (49.9x) | XXX | XXX | XXX |
| EV/EBIT | (38.0x) | XXX | (42.5x) | XXX | XXX | XXX |
| P/E | (42.0x) | XXX | (56.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (41.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified SanBio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
SanBio Margins & Growth Rates
SanBio's revenue in the last 12 month grew by 1180%.
SanBio's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.5M for the same period.
SanBio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1180% | XXX | — | XXX | XXX | XXX |
| EBITDA Margin | (888%) | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | (26%) | XXX | 26% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
SanBio Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| SanBio | XXX | XXX | XXX | XXX | XXX | XXX |
| SPIMACO - ADDWAEIH | XXX | XXX | XXX | XXX | XXX | XXX |
| MedinCell | XXX | XXX | XXX | XXX | XXX | XXX |
| Keqian Biology | XXX | XXX | XXX | XXX | XXX | XXX |
| Gen İlaç | XXX | XXX | XXX | XXX | XXX | XXX |
| Amphastar Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SanBio M&A Activity
SanBio acquired XXX companies to date.
Last acquisition by SanBio was on XXXXXXXX, XXXXX. SanBio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by SanBio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSanBio Investment Activity
SanBio invested in XXX companies to date.
SanBio made its latest investment on XXXXXXXX, XXXXX. SanBio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by SanBio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout SanBio
| When was SanBio founded? | SanBio was founded in 2013. |
| Where is SanBio headquartered? | SanBio is headquartered in Japan. |
| How many employees does SanBio have? | As of today, SanBio has over 43 employees. |
| Who is the CEO of SanBio? | SanBio's CEO is Keita Mori. |
| Is SanBio publicly listed? | Yes, SanBio is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of SanBio? | SanBio trades under 4592 ticker. |
| When did SanBio go public? | SanBio went public in 2015. |
| Who are competitors of SanBio? | SanBio main competitors are SPIMACO - ADDWAEIH, MedinCell, Keqian Biology, Gen İlaç. |
| What is the current market cap of SanBio? | SanBio's current market cap is $1B. |
| What is the current revenue of SanBio? | SanBio's last 12 months revenue is $3M. |
| What is the current revenue growth of SanBio? | SanBio revenue growth (NTM/LTM) is 1180%. |
| What is the current EV/Revenue multiple of SanBio? | Current revenue multiple of SanBio is 339.2x. |
| Is SanBio profitable? | No, SanBio is not profitable. |
| What is the current EBITDA of SanBio? | SanBio has negative EBITDA and is not profitable. |
| What is SanBio's EBITDA margin? | SanBio's last 12 months EBITDA margin is (888%). |
| What is the current EV/EBITDA multiple of SanBio? | Current EBITDA multiple of SanBio is (38.2x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.